SpringWorks Therapeutics, Inc. (SWTX)

Market Cap	2.78B
Revenue (ttm)	135.49M
Net Income (ttm)	-275.16M
Shares Out	74.37M
EPS (ttm)	-3.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,158,401
Open	38.58
Previous Close	37.93
Day's Range	36.75 - 38.58
52-Week Range	20.19 - 53.92
Beta	0.79
Analysts	Strong Buy
Price Target	64.50 (+72.28%)
Earnings Date	Nov 12, 2024

About SWTX

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer....

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 13, 2019
• Employees: 305
• Stock Exchange: NASDAQ
• Ticker Symbol: SWTX
• Website: https://www.springworkstx.com

Analyst Forecast

According to 6 analysts, the average rating for SWTX stock is "Strong Buy." The 12-month stock price forecast is $64.5, which is an increase of 72.28% from the latest price.

Price Target

$64.5

(72.28% upside)

Analyst Consensus: Strong Buy